Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Intravenous Vitamin C for Severe Acute Pancreatitis
NCT06897384Active, not recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ascorbic acid in acute pancreatitis (AP) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Mortality rate in ICU at 6 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
ascorbic acid
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on NCT06897384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897384.